- Key Insight: Learn how employers are integrating GLP‑1 drugs into broader benefit strategies.
- What’s at Stake: Rising drug access could shift insurer costs, retention strategies and benefit budgets.
- Supporting Data: Trump administration deal targets cost reductions for GLP‑1s Wegovy and Zepbound.
- Source: Bullets generated by AI with editorial review
A growing number of employers are offering weight loss drugs as part of their healthcare plans, while still promoting holistic programs and lifestyle changes as a long-term solution to physical fitness.
